Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC).

Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). Invest New Drugs. 2018 10; 36(5):919-926.

View in: PubMed

subject areas

Adult
Aged
Aged, 80 and over
Antineoplastic Agents
Bradycardia
Disease-Free Survival
Double-Blind Method
Humans
Male
Middle Aged
Neutropenia
Prostatic Neoplasms, Castration-Resistant
Protein Kinase Inhibitors
Proto-Oncogene Proteins c-met
Pyrrolidinones
Quinolines

authors with profiles

Russell Z. Szmulewitz
Walter M. Stadler